Abstract
Herpes simplex virus type-1 (HSV1) in which the neurovirulence factor ICP34.5 is inactivated has been shown to direct tumour-specific cell lysis in several tumour models. Such viruses have also been shown to be safe in Phase I clinical trials by intra-tumoral injection in glioma and melanoma patients.1,2,3 Previous work has used serially passaged laboratory isolates of HSV1 which we hypothesized may be attenuated in their lytic capability in human tumour cells as compared to more recent clinical isolates. To produce ICP34.5 deleted HSV with enhanced oncolytic potential, we tested two clinical isolates. Both showed improved cell killing in all human tumour cell lines tested compared to a laboratory strain (strain 17+). ICP34.5 was then deleted from one of the clinical isolate strains (strain JS1). Enhanced tumour cell killing with ICP34.5 deleted HSV has also been reported by the deletion of ICP47 by the up-regulation of US11 which occurs following this mutation.4,5 Thus to further improve oncolytic properties, ICP47 was removed from JS1/ICP34.5−. As ICP47 also functions to block antigen processing in HSV infected cells, this mutation was also anticipated to improve the immune stimulating properties of the virus. Finally, to provide viruses with maximum oncolytic and immune stimulating properties, the gene for human or mouse GM-CSF was inserted into the JS1/34.5−/47- vector backbone. GM-CSF is a potent immune stimulator promoting the differentiation of progenitor cells into dendritic cells and has shown promise in clinical trials when delivered by a number of means. Combination of GM-CSF with oncolytic therapy may be particularly effective as the necrotic cell death accompanying virus replication should serve to effectively release tumour antigens to then induce a GM-CSF-enhanced immune response. This would, in effect, provide an in situ, patient-specific, anti-tumour vaccine. The viruses constructed were tested in vitro in human tumour cell lines and in vivo in mice demonstrating significant anti-tumour effects. These were greatly improved compared to viruses not containing each of the modifications described. In vivo, both injected and non-injected tumours showed significant shrinkage or clearance and mice were protected against re-challenge with tumour cells. The data presented indicate that JS1/ICP34.5−/ICP47-/GM-CSF acts as a powerful oncolytic agent which may be appropriate for the treatment of a number of solid tumour types in man.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rampling R et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7: 859–866.
Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867–874.
MacKie RM, Stewart B, Brown SM . Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001; 357: 525–526.
He B et al. Suppression of the phenotype of gamma(1)34.5− herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997; 71: 6049–6054.
Mohr I et al. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001; 75: 5189–5196.
Hawkins LK, Lemoine NR, Kirn D . Oncolytic biotherapy: a novel therapeutic plafform. Lancet Oncol 2002; 3: 17–26.
Ring CJ . Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491–502.
Fujiwara T, Kataoka M, Tanaka N . Adenovirus-mediated p53 gene therapy for human cancer. Mol Urol 2000; 4: 51–54.
Xu G, McLeod HL . Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 2001; 7: 3314–3324.
Belldegrun A et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001; 12: 883–892.
Stewart AK et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 1999; 6: 350–363.
Ferrantini M, Belardelli F . Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin Cancer Biol 2000; 10: 145–157.
Kaushik A . Leuvectin Vical Inc. Curr Opin Investig Drugs 2001; 2: 976–981.
Chen Y et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001; 61: 5453–5460.
Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107–121.
MacLean AR, ul-Fareed M, Robertson L, Harland J, Brown SM . Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the ‘a’equence. J Gen Virol 1991; 72: 631–639.
Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938–943.
Yang CT et al. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 2001; 61: 5959–5963.
Chou J, Chen JJ, Gross M, Roizman B . Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5− mutants of herpes simplex virus 1. Proc Natl Acad Sci USA 1995; 92: 10516–10520.
He B, Gross M, Roizman B . The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997; 94: 843–848.
Lamont JP et al. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000; 7: 588–592.
Khuri FR et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879–885.
Ganly I et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798–806.
Reid T et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001; 8: 1618–1626.
Todo T, Martuza RL, Rabkin SD, Johnson PA . Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001; 98: 6396–6401.
Taneja S et al. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 2001; 98: 8804–8808.
Mohr I et al. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001; 75: 5189–5196.
Hill A et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375: 411–415.
Thompson RL et al. Functional and molecular analyses of the avirulent wild-type herpes simplex virus type 1 strain KOS. J Virol 1986; 58: 203–211.
Sedarati F, Stevens JG . Biological basis for virulence of three strains of herpes simplex virus type 1. J Gen Virol 1987; 68: 2389–2395.
Brown SM et al. Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5−negative herpes simplex virus types 1 and 2. J Gen Virol 1994; 75: 2367–2377.
McMenamin MM et al. A gamma34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. Neuroscience 1998; 83: 1225–1237.
Taneja S et al. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 2001; 98: 8804–8808.
Poppers J, Mulvey M, Khoo D, Mohr I . Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein. J Virol 2000; 74: 11215–11221.
Cassady KA, Gross M, Roizman B . The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. J Virol 1998; 72: 8620–8626.
Tomazin R et al. Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J Virol 1998; 72: 2560–2563.
Hill AB, Barnett BC, McMichael AJ, McGeoch DJ . HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol 1994; 152: 2736–2741.
Chahlavi A et al. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 1999; 6: 1751–1758.
Wong RJ et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 2001; 12: 253–265.
Toda M, Martuza RL, Rabkin SD . Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther 2000; 2: 324–329.
Bennett JJ et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg 2001; 233: 819–826.
Parker JN et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000; 97: 2208–2213.
Andreansky S et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 1998; 5: 121–130.
Dummer R . GVAX (Cell Genesys). Curr Opin Investig Drugs 2001; 2: 844–848.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liu, B., Robinson, M., Han, ZQ. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10, 292–303 (2003). https://doi.org/10.1038/sj.gt.3301885
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301885
Keywords
This article is cited by
-
A review of animal models utilized in preclinical studies of approved gene therapy products: trends and insights
Laboratory Animal Research (2024)
-
Review of cancer therapies for the perioperative physician
Perioperative Medicine (2023)
-
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Journal of Translational Medicine (2023)
-
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
Journal of Hematology & Oncology (2023)
-
Oncolytic virotherapy: basic principles, recent advances and future directions
Signal Transduction and Targeted Therapy (2023)